The Thrombolex leadership team has previously led the successful creation of various novel medical devices and start-up companies to include specialty stents enabling a transformational change in the endovascular treatment of obstructive lesions in the coronary, iliac, renal and carotid arteries. More recently - addressing th treatment of arterial and venous thromboembolic conditions - the team has focused on solutions to the under-recognized and under-treated problems associated with these conditions. The outcome has been the creation of BASHIR™ Endovascular Catheters providing a unique platform technology for use in the treatment of arterial and venous thromboembolic (A+VTE) conditions.
